Delayed neurologic deterioration from vasospasm remains the greatest cause of morbidity and mortality following subarachnoid hemorrhage. The authors assess the incidence and clinical course of symptomatic vasospasm following subarachnoid hemorrhage using a uniform management protocol over a 24-month period. One hundred eighteen consecutive patients were admitted to the neurovascular surgery service within 2 weeks of subarachnoid hemorrhage not attributed to trauma, tumor, or vascular malformation (113 patients had aneurysms). Early surgery was performed whenever possible, and hypertensive hypervolemk hemodilution therapy was instituted at the first sign of clinical vasospasm. Forty-two patients ( 
D
ELAYED neurologic deterioration from vaso-I spasm remains the greatest cause of death and major disability following subarachnoid hemorrhage (SAH). 1 -* It has recently been estimated that 7% of patients reaching referral centers will die or be severely disabled by recurrent hemorrhage, while 14% will succumb to or be maimed by ischemic complications of vasospasm. 3 While early surgery can be expected to effectively minimize rebleeding, there continues to be concern that such intervention might aggravate and worsen the outcome from vasospasm. Others suggest that early surgery might allow more aggressive medical management of clinical vasospasm (in the absence of an undipped aneurysm), and might Since 1983, a uniform protocol for the management of SAH has been adopted at the Barrow Neurological Institute. Early surgery is performed whenever possible, and patients are aggressively treated with hypertensive hypervolemic hemodilution at the first sign of clinical vasospasm. The objective of this report was to assess the incidence of clinical vasospasm with this management strategy, to evaluate the response of this condition to hypervolemic hemodilution therapy, and to define and discuss management complications.
Subjects and Methods
From January 1984 to December 1985, 118 consecutive patients (ages 20-77; median age 49) were admitted to the Neurovascular Surgery Service at the Barrow Neurological Institute within 2 weeks of SAH not attributed to trauma, tumor, or vascular malformation. The diagnosis was confirmed by computed tomography (CT) or lumbar puncture in all cases. All patients had complete cerebral angiography via retrograde femoral artery catheterization on the day of ad-mission. An aneurysm was demonstrated on the initial angiogram in 112 cases and on a subsequent angiogram 1 week later in 1 case. In the remaining 5 patients, no aneurysm was demonstrated.
Patients were managed according to a uniform protocol ( Figure 1) . Craniotomy was performed within 24 hours of admission unless the patient already exhibited signs and symptoms of clinical vasospasm or was otherwise a poor surgical candidate (comatose without mass lesion, unstable hemodynamic status, etc.). At surgery, it was uniform policy to open the arachnoid cisterns widely and to clear all accessible subarachnoid clot in addition to clipping or wrapping the aneurysm.
Clinical vasospasm was defined as delayed neurologic deterioration that could not be attributed to rebleeding, hydrocephalus, intracerebral hematoma, electrolyte abnormalities, or toxic and metabolic factors.'• 3 -311 It usually followed a stereotyped course, with gradual blunting of the level of consciousness starting 3-10 days after SAH, followed within hours by focal neurologic deficits. At the first suggestion of clinical vasospasm, a central venous catheter was introduced; a pulmonary artery catheter (Swan-Ganz catheter) was used if the patient had preexisting cardiac or pulmonary disease. Simultaneously, necessary diagnostic tests were obtained to rule out other causes of delayed neurologic deterioration. Once the diagnosis of clinical vasospasm was established, hypervolemic hemodilution was initiated under the guidance of a consulting cardiologist.
The Neurologic status was graded using a modified Hunt-Hess scale (Table 1 ). This was determined on admission in all patients with SAH and on a daily basis in all patients with clinical vasospasm. The progress of the latter patients, including pertinent hemodynamic parameters and laboratory data, was closely monitored in a prospective fashion by a full-time clinical research nurse.
Results

Incidence of Clinical Vasospasm
Of the 118 patients admitted within 2 weeks of SAH, 42 (35.6%) developed clinical vasospasm. These cases represented 41 of 113 cases (36.3%) with proven aneurysm, and 1 of 5 cases (20%) in which no aneurysm could be identified. Patients with tumor, trauma, or vascular malformations had been excluded. Clinical vasospasm developed in 9 of 28 patients (32.1%) who were Grade I at the time of admission, in 16 of 44 patients (36.4%) who were Grade II on admission, in 10 of 22 patients (45.5%) who were Grade III on admission, and in 7 of 16 patients (43.8%) who were Grade IV on admission. There was no delayed neurologic deterioration attributable to vasospasm in any of the 8 patients who were comatose (Grade V) on admission.
Clinical vasospasm developed and was treated after craniotomy in 27 cases operated in the acute state (within 24 hours of admission). It was present and treated prior to delayed surgery in 10 cases. An additional 5 patients with clinical vasospasm never underwent definitive craniotomy (4 because of death from vasospasm and 1 because no aneurysm was identified). Twenty-two of the 42 patients with clinical vasospasm required adjunctive cerebrospinal fluid diversion.
Response to Hypervolemic Hemodilution Therapy
Neurologic grades on admission, at initiation of hypervolemic hemodilution therapy (onset of clinical vasospasm), and at conclusion of hypervolemic hemodilution therapy (resolution of clinical vasospasm) are illustrated in Figure 2 . Forty-one of the 42 patients had deteriorated to Grade IH or worse at the onset of clinical vasospasm. Sustained improvement by at least 1 neurologic grade was observed in 60% of the patients, while 24% had no change in neurologic grade, and 16% worsened or died during hypervolemic hemodilution therapy. Sustained improvement was most likely to occur in clinical vasospasm patients who were Grades I or II on admission, while continued deterioration was most frequently encountered among patients who were Grade IV on admission (Figure 3 ). Upon resolution of clinical vasospasm, 48% of the patients were neurologically normal (Grade I), 33% had a minor neurologic deficit (Grades II or HI), and 19% had a major neurologic deficit or died (Grades IV or V). Overall, death or major neurologic deficit from vasospasm occurred in 6.7% of all patients with SAH.
Diagnostic and Laboratory Data
The desired hemodynamic objectives were approached or achieved in all patients. Mean hematocrit was 38.4 ± 3.3% on admission, 37.1 ± 3.1% at onset of hypervolemic hemodilution therapy, and 33.0 ± 1.9% at the conclusion of hypervolemic hemodilution therapy. Mean sodium concentration was 137.7 ±2.0 mEq/dl on admission, 141.6 ±2.6 mEq/dl at the onset of hypervolemic hemodilution therapy, and 140.7 ± 3.1 mEq/dl at the conclusion of hypervolemic hemodilution therapy. In some patients, neurologic deficits fluctuated markedly with changes in arterial pressure despite optimal volume status (Figure 4) . In other patients, neurologic deficits fluctuated markedly with changes in volume status despite maximal hypertension ( Figure 5 ). Close titration of all parameters was therefore essential throughout the duration of clinical vasospasm. Improvement in clinical status frequently occurred within minutes of the initiation of therapy.
Cerebral angiography was performed at least once during the period of clinical vasospasm in 39 patients. It revealed definite angiographic spasm (to a blinded radiologist) in all cases. Regional cerebral blood flow measurements (using the stable xenon-CT technique) were performed in 10 patients and showed focal areas of hypoperfusion in all cases ( Figure 6 ).
Cases with Poor Outcome and Management Complications
Eight patients with clinical vasospasm had a poor outcome (worse than Grade IE upon resolution of clinical vasospasm). One patient was Grade III on admission to the hospital and had clinical vasospasm at that time; he was receiving normotensive hypervolemic hemodilution therapy while awaiting delayed clipping of an anterior communicating artery aneurysm when he rebled and died 5 days after SAH. Coagulation parameters and platelet count were normal at all times, and systolic arterial pressure never exceeded 150 mm Hg prior to the rebleed.
One patient was Grade II on admission 3 days after SAH; he developed a dense hemiparesis within hours of admission and died of progressive vasospasm 1 week later. An additional 4 patients (including 2 with mycotic aneurysms) were already in fulminant clinical vasospasm (Grade IV) on admission to the hospital; 3 died of progressive spasm before surgical intervention, and 1 recovered with residual left hemiparesis and homonymous hemianopsia. Another 2 patients in poor neurologic condition on admission (Grade IV) had further deterioration from vasospasm after an early operation for evacuation of a hematoma (and aneurysm clipping); both died despite hypertensive hypervolemic hemodilution therapy. No Grade I or II patient operated in the acute state sustained a severe permanent neurologic deficit or died as a result of vasospasm.
Three patients developed respiratory failure with frank pulmonary edema during hypervolemic hemodilution therapy. All 3 had central venous pressure monitoring. In 1 case (a 47-year-old healthy woman) the central venous pressures were > 15 mm Hg for several hours before decompensation, and she received no diuretics or fluid restriction. This patient deviated from our management protocol. The other 2 cases (a 34-year-old severely asthmatic woman and a 69-year-old man with cardiac disease) decompensated despite normal central venous pressures. The latter required endotracheal intubation. All 3 patients responded to appropriate diuresis, and all made excellent recovery. These 3 complications could have been prevented by judicious attention to the hemodynamic parameters and through prophylactic use of a Swan-Ganz catheter in the presence of preexisting pulmonary or cardiac disease. There were no complications attributed to catheter insertion or care. There were no instances of worsened ischemic brain edema or hemorrhagic infarction.
Discussion
Angiographic evidence of vasospasm is encountered in 60-80% of patients with SAH.
3 -512 - 14 It is most frequently seen between the fourth and tenth days posthemorrhage and is most severe around the sixth day. 13 The presence and extent of angiographic vasospasm correlate strongly with the severity of the hemorrhage as determined by the amount of blood in the subarachnoid cisterns on CT scans. 1516 The precise incidence of angiographic spasm in a given series is difficult to determine and obviously depends on the particular mix of patients (mild vs. severe hemorrhage, type of aneurysm, etc.), the timing and quality of angiography, and the definition of spasm.
While many patients with angiographic vasospasm do not seem to suffer any adverse consequences, others develop a stereotyped clinical syndrome apparently related to brain ischemia.
3~6 '"' 13 Symptomatic or clinical vasospasm most frequently occurs during the period of most intense angiographic spasm and is characterized by gradual worsening of the sensorium, followed within hours by fluctuating focal neurologic deficits. The syndrome resolves several days (rarely weeks) later, with gradual improvement in the sensorium. Delayed neurologic deterioration from vasospasm affects over one-third of patients with SAH and kills or severely disables nearly half of these patients. 336 It has been estimated that clinical vasospasm kills approximately 7% and severely disables another 7% of SAH patients currently reaching referral centers. 23 While many pharmacologic approaches have been suggested in an effort to prevent or reduce arterial narrowing, the experimental evidence remains conflicting, and no agent has achieved widespread acceptance in clinical circles. 17 The mainstay of current management of vasospasm has remained aggressive, supportive care and optimization of the hemodynamic status. While most aneurysm surgeons accept these broad objectives, there is no uniform agreement on the specific use of hypertension, hypervolemia, or hemodilution. Furthermore, the literature is limited regarding the effect of these modalities on patient outcome.
In 1967, Farhat and Schneider published their observations on the improvement of ischemic neurologic deficits with increased systemic blood pressure. 18 Since that time, Simeone and others have emphasized the theoretical rationale for hypertensive therapy.
19 " Regional cerebral blood flow is depressed and pressure autoregulation is clearly impaired in clinical vasospasm. 20 ' 2 ' 123 Cerebral blood flow is directly dependent on perfusion pressure under these circumstances. Despite this compelling rationale, clinicians have been reluctant to use this modality on a large scale for fear of increasing intracranial pressure, precipitating hemorrhage into an area of infarction, worsening ischemic edema, or rupturing an undipped aneurysm. However, judicious control of intracranial pressure, timely therapy prior to frank infarction, and early clipping of the aneurysm can circumvent most of these concerns. There were no instances of hemorrhagic infarction or intractable cerebral edema in this series. The only patient with aneurysmal rebleed was not on hypertensive therapy.
Hypervolemia with or without hypertension has been advocated by several surgeons."
2224 - 26 The theoretical rationale for hypervolemia is based on evidence that S AH results in contraction of the extracellular and vascular spaces, perhaps because of cerebral salt wasting or other mechanisms. 2728 Furthermore, hypervolemia increases cardiac output and facilitates hypertensive therapy. 24 In 1976, Kosnik and Hunt reported the reversal of ischemic symptoms in 6 of 7 patients using vasopressors and hypervolemia. 22 In 1977, Gianotta et al reported success with these modalities in 15 of 17 patients. 23 In 1978, Pritz and coworkers reported an additional 4 such cases and emphasized the importance of aggressive monitoring of hemodynamic parameters during such therapy. 24 The largest series to date was published by Kassell et al in 1982 , reporting on the responses of 58 patients with the strict diagnosis of clinical vasospasm. 26 The patients represented consecutive cases treated with hypertensive hypervolemia at 2 large centers. While the management protocol aimed for a hematocrit of 40%, some patients received colloid agents and may have been subjected to an element of adjunctive hemodilution. Sustained neurologic improvement was documented in 74% of the patients. There were 10 cases of pulmonary edema and 3 rebleeds during the period of therapy. There were no cases of hemorrhagic infarction or increased brain swelling associated with the treatment. The problem with these and other reports has been the retrospective nature of patient identification. Also, there was no information regarding other vasospasm cases (if any) or the overall number of patients with SAH managed during the same time period (Table 2) .
The use of hemodilution as an adjunct to hypertensive hypervolemia remains controversial. Hemodilution results in a dramatic decrease in blood viscosity. 29 - 30 This change occurs at hematocrit levels well within the physiologic range and is more pronounced at lower shear rates (i.e., in constricted vessels and at low flow rates). 30 Hemodilution has been shown to increase regional cerebral flow in the ischemic core (even in the absence of adjunctive hypervolemia) and to decrease infarct size in experimental focal cerebral ischemia.
2931 " 33 More recently, Kee and Wood have demonstrated an increase in blood flow and oxygen transport across tight stenoses by hemodilution to a hematocrit of 34%.
M Other clinical reports have emphasized the harmful sequelae of an elevated hematocrit after cerebral infarction. 3336 Conversely, critics of hemodilution caution that blood oxygen content decreases with decreasing hematocrit, and that some of the improvement in regional cerebral blood flow may toe the result of such hypoxemia. The optimal hematocrit thought to maximize oxygen delivery to tissue has been estimated at 33%, but may be higher in the ischemic brain. 293337 In the Barrow Neurological Institute protocol, either extreme was avoided by aggressively lowering the hematocrit in a patient when it was above 40%, and by aiming for a hematocrit in the mid-30's in all patients.
Sustained neurologic improvement by at least 1 grade occurred in 60% of all patients with vasospasm. Improvement was most likely to occur with hypervolemic hemodilution therapy if vasospasm followed early clipping of the aneurysm (patient in good neurologic condition on admission and deterioration from vasospasm in the postoperative period). None of 25 such patients sustained a major permanent neurologic deficit or died from vasospasm. Continued deterioration from vasospasm was most likely to occur in poor grade (Grades IV and V) patients already in fulminant vasospasm on admission to the hospital. Management complications were limited to 3 cases of pulmonary congestion. All 3 should have been avoided by closer monitoring of hemodynamic parameters. As in Kassell's series, there were no instances of worsened brain edema or hemorrhagic infarction. The formal evaluation of late outcome, including possible neuropsychological sequelae, was not within the scope of this study.
While early operative intervention might be expected to increase the incidence of clinical vasospasm, such was not the case in this series. The 35.6% incidence of clinical vasospasm following SAH is comparable to the 33.5% incidence reported in the recent cooperative study on the timing of aneurysm surgery. It is only slightly higher than the 26.7% incidence in the placebo limb of the nimodipine cooperative trial (which included only Grade I patients admitted within 96 hours of hemorrhage).' Outcome from vasospasm compared favorably with either series (Table 2) . Death or major neurologic deficit attributed to vasospasm (defined quite liberally as worse than Grade III upon resolution of vasospasm) afflicted only 6.7% of all SAH patients in this institution. In contrast, vasospasm killed or severely disabled 16% of patients in the cooperative study and 13.3% of patients in the placebo limb of the nimodipine study. 12 The difference would be greater if rebleeding that occurred during the period of vasospasm were excluded (as it was in these other series), and if patients with mycotic aneurysms were excluded. Since the SAH populations were not concurrent and were not necessarily comparable, no firm statistical conclusions can be drawn. However, the results in this prospectively surveyed SAH population (subjected to a uniform management protocol at a sin- Pts, patients; SAH, subarachnoid hemorrhage; CV, clinical vasospasm; %, percent of total patients with subarachnoid hemorrhage.
•Percent of total patients with clinical vasospasm. tExcluding death or disability due to rebleeding during period of clinical vasospasm. gle institution) should provide a reference for comparing outcomes with other management modalities and serve as a guideline for more controlled randomized trials in the future.
In conclusion, the authors propose that early operative intervention for aneurysmal SAH and subsequent aggressive medical management of vasospasm with hypervolemic hemodilution therapy can be accomplished safely and without worsening the outcome from vasospasm. It is hoped that such a management strategy might lower the incidence of death and disability from vasospasm subsequent to SAH.
